From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound

RobatumumabMonoclonal antibodyTypeWhole antibodySourceHumanTargetCD221Clinical dataATC codenoneIdentifiersCAS Number934235-44-6 NChemSpidernoneUNIIV983921H3BKEGGD10056 NChemical and physical dataFormulaC6418H9960N1732O1992S42Molar mass144602.93 g·mol−1 NY (what is this?)  (verify)
Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.[1]
Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete.[2][3] Merck has since discontinued development.[4]

References[edit]


^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines (2008). Encrenaz C (ed.). "Proposed International Nonproprietary Names: List 100" (PDF). WHO Drug Information. 22 (4): 311–67.

^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. (October 2016). "A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma". Pediatric Blood & Cancer. 63 (10): 1761–70. doi:10.1002/pbc.26087. PMC 5129487. PMID 27362300.

^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov

^ "Robatumumab". Adis Insight. Springer Nature Switzerland AG.


vteMonoclonal antibodies for tumorsTumorHuman
Adecatumumab§
Amivantamab
Ascrinvacumab§
Atezolizumab (+hyaluronidase)
Balstilimab†
Botensilimab
Cixutumumab§
Conatumumab§
Cosibelimab
Daratumumab
Drozitumab§
Duligotumab§
Dusigitumab§
Enfortumab vedotin
Enoticumab§
Figitumumab§
Flanvotumab§
Ganitumab†
Glembatumumab vedotin†
Intetumumab§
Ipilimumab
Iratumumab§
Istiratumab
Icrucumab§
Lexatumumab§
Linvoseltamab
Lucatumumab§
Mapatumumab§
Narnatumab§
Necitumumab
Nesvacumab§
Nivolumab# (+hyaluronidase, +relatlimab)
Ofatumumab
Olaratumab†
Panitumumab
Patritumab§
Pembrolizumab#
Pritumumab§
Radretumab§
Ramucirumab
Rilotumumab†
Robatumumab§
Seribantumab§
Sugemalimab
Tarextumab§
Tisotumab vedotin
Teprotumumab†
Tovetumab§
Vantictumab§
Votumumab§
Zalutumumab†
Mouse
Abagovomab
Altumomab pentetate
Anatumomab mafenatox
Arcitumomab
Bectumomab
Blinatumomab
Capromab pendetide
Detumomab
Edrecolomab
Ibritumomab tiuxetan
Igovomab
Lilotomab
Minretumomab
Mitumomab
Nacolomab tafenatox
Moxetumomab pasudotox
Naptumomab estafenatox
Oregovomab
Pemtumomab†
Racotumomab
Satumomab pendetide
Solitomab
Taplitumomab paptox
Nofetumomab merpentan
Pintumomab
Tenatumomab
Tositumomab
Chimeric
Amatuximab§
Bavituximab§
Brentuximab vedotin
Carotuximab†
Cetuximab
Derlotuximab biotin§
Dinutuximab
Ecromeximab§
Ensituximab§
Futuximab§
Girentuximab†
Indatuximab ravtansine§
Isatuximab
Loncastuximab tesirine
Margetuximab
Mirvetuximab soravtansine
Rituximab#
Siltuximab
Ublituximab
Zolbetuximab
Humanized
Abituzumab§
Alemtuzumab
Axatilimab
Belantamab mafodotin
Bevacizumab
Bivatuzumab mertansine§
Brontictuzumab§
Cantuzumab mertansine§
Cantuzumab ravtansine§
Cirmtuzumab
Citatuzumab bogatox§
Clivatuzumab tetraxetan
Cofetuzumab pelidotin
Dacetuzumab§
Demcizumab§
Dalotuzumab§
Datopotamab deruxtecan
Denintuzumab mafodotin§
Elotuzumab
Emactuzumab
Emibetuzumab§
Enoblituzumab§
Epcoritamab
Etaracizumab§
Farletuzumab§
Ficlatuzumab§
Flotetuzumab§
Gemtuzumab ozogamicin
Glofitamab
Imgatuzumab§
Inotuzumab ozogamicin
Labetuzumab§
Lifastuzumab vedotin§
Lintuzumab§
Lorvotuzumab mertansine§
Lumretuzumab§
Matuzumab§
Milatuzumab§
Naxitamab
Nimotuzumab†
Obinutuzumab
Ocaratuzumab§
Odronextamab
Otlertuzumab§
Onartuzumab§
Oportuzumab monatox†
Parsatuzumab§
Penpulimab
Pertuzumab
Pinatuzumab vedotin§
Polatuzumab vedotin
Rosmantuzumab
Rovalpituzumab tesirine†
Sacituzumab govitecan
Sibrotuzumab§
Simtuzumab§
Sofituzumab vedotin§
Tacatuzumab tetraxetan§
Tigatuzumab§
Trastuzumab# (+deruxtecan / +emtansine)
Tucotuzumab celmoleukin§
Vandortuzumab vedotin§
Vanucizumab§
Veltuzumab§
Vorsetuzumab mafodotin§
Zenocutuzumab
Rat/mouse hybrid
Catumaxomab
Ertumaxomab§
Chimeric + humanized
Depatuxizumab mafodotin†
Duvortuxizumab
Ontuxizumab§

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteGrowth factor receptor modulatorsAngiopoietin
Agonists: Angiopoietin 1
Angiopoietin 4
Antagonists: Angiopoietin 2
Angiopoietin 3
Kinase inhibitors: Altiratinib
CE-245677
Rebastinib
Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)
CNTF
Agonists: Axokine
CNTF
Dapiclermin
EGF (ErbB)EGF(ErbB1/HER1)
Agonists: Amphiregulin
Betacellulin
EGF (urogastrone)
Epigen
Epiregulin
Heparin-binding EGF-like growth factor (HB-EGF)
Murodermin
Nepidermin
Transforming growth factor alpha (TGFα)
Kinase inhibitors: Afatinib
Agerafenib
Brigatinib
Canertinib
Dacomitinib
Erlotinib
Gefitinib
Grandinin
Icotinib
Lapatinib
Neratinib
Osimertinib
Vandetanib
WHI-P 154
Antibodies: Cetuximab
Depatuxizumab
Depatuxizumab mafodotin
Futuximab
Imgatuzumab
Matuzumab
Necitumumab
Nimotuzumab
Panitumumab
Zalutumumab
ErbB2/HER2
Agonists: Unknown/none
Antibodies: Ertumaxomab
Pertuzumab
Trastuzumab
Trastuzumab deruxtecan
Trastuzumab duocarmazine
Trastuzumab emtansine
Kinase inhibitors: Afatinib
Lapatinib
Mubritinib
Neratinib
Tucatinib
ErbB3/HER3
Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))
Antibodies: Duligotumab
Patritumab
Seribantumab
ErbB4/HER4
Agonists: Betacellulin
Epigen
Heparin-binding EGF-like growth factor (HB-EGF)
Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))
FGFFGFR1
Agonists: Ersofermin
FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin
Selpercatinib
Trafermin
Velafermin
FGFR2
Agonists: Ersofermin
FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
Palifermin
Repifermin
Selpercatinib
Sprifermin
Trafermin
Antibodies: Aprutumab
Aprutumab ixadotin
Kinase inhibitors: Infigratinib
FGFR3
Agonists: Ersofermin
FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)
Selpercatinib
Sprifermin
Trafermin
Antibodies: Burosumab (against FGF23)
FGFR4
Agonists: Ersofermin
FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)
Trafermin
Unsorted
Agonists: FGF15/19
HGF (c-Met)
Agonists: Fosgonimeton
Hepatocyte growth factor
Potentiators: Dihexa (PNB-0408)
Kinase inhibitors: Altiratinib
AM7
AMG-458
Amuvatinib
BMS-777607
Cabozantinib
Capmatinib
Crizotinib
Foretinib
Golvatinib
INCB28060
JNJ-38877605
K252a
MK-2461
PF-04217903
PF-2341066
PHA-665752
SU-11274
Tivantinib
Volitinib
Antibodies: Emibetuzumab
Ficlatuzumab
Flanvotumab
Onartuzumab
Rilotumumab
Telisotuzumab
Telisotuzumab vedotin
IGFIGF-1
Agonists: des(1-3)IGF-1
Insulin-like growth factor-1 (somatomedin C)
IGF-1 LR3
Insulin-like growth factor-2 (somatomedin A)
Insulin
Mecasermin
Mecasermin rinfabate
Kinase inhibitors: BMS-754807
Linsitinib
NVP-ADW742
NVP-AEW541
OSl-906
Antibodies: AVE-1642
Cixutumumab
Dalotuzumab
Figitumumab
Ganitumab
Robatumumab
R1507
Teprotumumab
Xentuzumab (against IGF-1 and IGF-2)
IGF-2
Agonists: Insulin-like growth factor-2 (somatomedin A)
Antibodies: Dusigitumab
Xentuzumab (against IGF-1 and IGF-2)
Others
Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)
Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
Trofinetide
LNGF (p75NTR)
Agonists: BDNF
BNN-20
BNN-27
Cenegermin
DHEA
DHEA-S
NGF
NT-3
NT-4
Antagonists: ALE-0540
Dexamethasone
EVT-901 (SAR-127963)
Testosterone
Antibodies: Against NGF: ABT-110 (PG110)
ASP-6294
Fasinumab
Frunevetmab
Fulranumab
MEDI-578
Ranevetmab
Tanezumab
Aptamers: Against NGF: RBM-004
Decoy receptors: LEVI-04 (p75NTR-Fc)
PDGF
Agonists: Becaplermin
Platelet-derived growth factor (A, B, C, D)
Kinase inhibitors: Agerafenib
Avapritinib
Axitinib
Crenolanib
Imatinib
Lenvatinib
Masitinib
Motesanib
Nintedanib
Pazopanib
Radotinib
Quizartinib
Ripretinib
Sunitinib
Sorafenib
Toceranib
Antibodies: Olaratumab
Ramucirumab
Tovetumab
RET (GFL)GFRα1
Agonists: Glial cell line-derived neurotrophic factor (GDNF)
Liatermin
Kinase inhibitors: Vandetanib
GFRα2
Agonists: Neurturin (NRTN)
Kinase inhibitors: Vandetanib
GFRα3
Agonists: Artemin (ARTN)
Kinase inhibitors: Vandetanib
GFRα4
Agonists: Persephin (PSPN)
Kinase inhibitors: Vandetanib
Unsorted
Kinase inhibitors: Agerafenib
SCF (c-Kit)
Agonists: Ancestim
Stem cell factor
Kinase inhibitors: Agerafenib
Axitinib
Dasatinib
Imatinib
Masitinib
Nilotinib
Pazopanib
Quizartinib
Sorafenib
Sunitinib
Toceranib
TGFβ
See here instead.
TrkTrkA
Agonists: Amitriptyline
BNN-20
BNN-27
Cenegermin
DHEA
DHEA-S
Gambogic amide
NGF
Tavilermide
Antagonists: ALE-0540
Dexamethasone
FX007
Testosterone
Negative allosteric modulators: VM-902A
Kinase inhibitors: Altiratinib
AZD-6918
CE-245677
CH-7057288
DS-6051
Entrectinib
GZ-389988
K252a
Larotrectinib
Lestaurtinib
Milciclib
ONO-4474
ONO-5390556
PLX-7486
Rebastinib
SNA-120 (pegylated K252a))
Antibodies: Against TrkA: GBR-900; Against NGF: ABT-110 (PG110)
ASP-6294
Fasinumab
Frunevetmab
Fulranumab
MEDI-578
Ranevetmab
Tanezumab
Aptamers: Against NGF: RBM-004
Decoy receptors: ReN-1820 (TrkAd5)
TrkB
Agonists: 3,7-DHF
3,7,8,2'-THF
4'-DMA-7,8-DHF
7,3'-DHF
7,8-DHF
7,8,2'-THF
7,8,3'-THF
Amitriptyline
BDNF
BNN-20
Deoxygedunin
Deprenyl
Diosmetin
DMAQ-B1
HIOC
LM22A-4
N-Acetylserotonin
NT-3
NT-4
Norwogonin (5,7,8-THF)
R7
R13
TDP6
Antagonists: ANA-12
Cyclotraxin B
Gossypetin (3,5,7,8,3',4'-HHF)
Ligands: DHEA
Kinase inhibitors: Altiratinib
AZD-6918
CE-245677
CH-7057288
DS-6051
Entrectinib
GZ-389988
K252a
Larotrectinib
Lestaurtinib
ONO-4474
ONO-5390556
PLX-7486
TrkC
Agonists: BNN-20
DHEA
NT-3
Kinase inhibitors: Altiratinib
AZD-6918
CE-245677
CH-7057288
DS-6051
Entrectinib
GZ-389988
K252a
Larotrectinib
Lestaurtinib
ONO-4474
ONO-5390556
PLX-7486
VEGF
Agonists: Placental growth factor (PGF)
Ripretinib
Telbermin
VEGF (A, B, C, D (FIGF))
Allosteric modulators: Cyclotraxin B
Kinase inhibitors: Agerafenib
Altiratinib
Axitinib
Cabozantinib
Cediranib
Fruquintinib
Lapatinib
Lenvatinib
Motesanib
Nintedanib
Pazopanib
Pegaptanib
Rebastinib
Regorafenib
Semaxanib
Sorafenib
Sunitinib
Toceranib
Tivozanib
Vandetanib
WHI-P 154
Antibodies: Alacizumab pegol
Bevacizumab
Icrucumab
Ramucirumab
Ranibizumab
Decoy receptors: Aflibercept
Others
Additional growth factors: Adrenomedullin
Colony-stimulating factors (see here instead)
Connective tissue growth factor (CTGF)
Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
Erythropoietin (see here instead)
Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
Glia maturation factor (GMF)
Hepatoma-derived growth factor (HDGF)
Interleukins/T-cell growth factors (see here instead)
Leukemia inhibitory factor (LIF)
Macrophage-stimulating protein (MSP; HLP, HGFLP)
Midkine (NEGF2)
Migration-stimulating factor (MSF; PRG4)
Oncomodulin
Pituitary adenylate cyclase-activating peptide (PACAP)
Pleiotrophin
Renalase
Thrombopoietin (see here instead)
Wnt signaling proteins
Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.vte
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.vte




Retrieved from "https://en.wikipedia.org/w/index.php?title=Robatumumab&oldid=1138419214"Categories: Drugs not assigned an ATC codeMonoclonal antibodiesExperimental cancer drugsMonoclonal antibody stubsAntineoplastic and immunomodulating drug stubsHidden categories: Articles with short descriptionShort description matches WikidataShort description is different from WikidataArticles with changed CASNo identifierChemicals that do not have a ChemSpider ID assignedArticles with changed KEGG identifierArticles without EBI sourceChemical pages without DrugBank identifierArticles without InChI sourceDrugs with no legal statusDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs that are a monoclonal antibodyAll stub articles